Competition for prescription of drugs that prevent sleepiness and manage so-called narcolepsy has begun. According to related industries, competition with Teva Handok's Nuvigil (Armodafinil) is expected as Wakix (Pitolisant) of Mitsubishi Tanabe Pharma will be applied from next month (February). Wakix is a counteractive and antagonist that selectively binds to histamine H3 receptors and is a new mechanism for increasing histamine concentration in the brain. Nuvigil, an active isomer of the sleep attack treatment Provigil, is a drug that promotes awakening by activating dopamine in the brain and improves the duration of existing drugs.

Mitsubishi Tanabe Pharma is currently undergoing prescription procedu